[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"abpa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:abpa":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633752","real-world-effectiveness-of-benralizumab-in-allergic-bronchopulmonary-aspergillosis-100633752",false,"NCT07530770","Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis","Effectiveness and Safety of Benralizumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience","Inclusion Criteria:\n\n* Female and Male patients aged 18-75 years inclusively at the time of Visit 1 with a physician diagnosis of Allergic Bronchopulmonary Aspergillosis has met the ISHAM Working Group Diagnostic Criteria for ABPA:\n\nPredisposing condition: Bronchial asthma Obligatory criteria (both should be present)\n\nType I aspergillus skin test positive (immediate cutaneous hypersensitivity Aspergillus antigen) or elevated IgE level against Aspergillus fumigatus (Af) Aspergillus niger or Aspergillus flavus may be eligible provided antigen-specific IgE and IgG measurements are available for use.\n\nElevated total IgE levels (\\>1,000IU\u002FmL)\\* Other criteria (at least two of three)\n\nPresence of precipitating or IgG antibodies against Af in serum Radiographic pulmonary opacities consistent with ABPA Total eosinophil count \\>500 cells\u002FuL in steroid naïve patients (may be historical)\n\n(if the patient meets all other criteria, an IgE value \\\u003C1,000 IU\u002FmL may be acceptable) Severe chronic asthma (for at least 12 months) requiring treatment with high dose ICS plus asthma controller prior to Visit 1\n\nOther acceptable asthma controllers include long acting bronchodilators (e.g. a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), a leukotriene inhibitor, theophylline preparations and\u002For maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control Documented current treatment with high daily doses of ICS ( \\>500ug of FP equivalent) plus at least one other asthma controller for at least 3 months prior to Visit 1\n\nFor ICS\u002FLABA combination preparation, highest-strength maintenance doses approved in the U.S. will meet this criterion If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose for 3 months prior to entering the study.\n\nHistory of at least 2 asthma exacerbations while on ICS plus another asthma controller (see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids (IM, IV, or oral) in the 12 months prior to Visit 1. For patients receiving oral corticosteroids as a maintenance therapy, an exacerbation is defined as a temporary increase of their maintenance dose for a minimum of 3 days.\n\nWeight \\> 40kg\n\nExclusion Criteria:\n\n* Clinical important pulmonary disease other than asthma with allergic bronchopulmonary aspergillosis (ie. chronic obstructive pulmonary disease (COPD), cystic fibrosis, sarcoid, and pulmonary fibrosis) History of anaphylaxis to any biologic therapy Known history of allergy or hypersensitivity reaction to benralizumab or any of its components Current smokers or former smokers with a smoking history of \\> 10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1.\n\nCurrently pregnant, breastfeeding, or lactating women Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis",[25,26,27],"Allergic Bronchopulmonary Aspergillosis","Severe Asthma","ABPA",[27,29],"Benralizumab","RECRUITING","2026-04-16",{"date":33,"type":34},"2026-04-21","ACTUAL",{"date":36,"type":34},"2025-09-01",{"date":38,"type":21},"2026-12-01",{"name":40,"class":41},"Qianfoshan Hospital","OTHER",2,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100620828","a-cohort-study-of-the-efficacy-and-safety-of-biologics-in-patients-with-abpa-100620828","NCT07362693","A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).\n2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.\n3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.\n4. Blood eosinophil count ≥150 cells \u002FμL.\n5. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;\n2. Known allergic history to biological agents;\n3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;\n4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n5. Pregnant or lactating women;\n6. Currently participating in other interventional clinical research;\n7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":51,"type":21},50,"2 Years","To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.",[27,55,56,57,25,58],"Biologics","Allergic Bronchopulmonary Aspergillosis (ABPA)","Cohort Study","Efficacy and Safety",[60,25,55],"abpa",{"date":62,"type":34},"2026-04-17",{"date":64,"type":34},"2025-01-31",{"date":66,"type":21},"2028-12-31",{"name":40,"class":41},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":78,"conditions":79,"keywords":84,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":93,"locationsCount":68},"100620826","a-study-of-the-efficacy-and-safety-of-bronchoscopic-airway-clearance-and-amphotericin-b-spraying-in-patients-with-abpa-100620826","NCT07362667","A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).\n2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a \\> 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.\n3. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);\n2. Patients with absolute or relative contraindications to electronic bronchoscopy;\n3. Known history of allergy to amphotericin B or any of its excipients;\n4. Patients with bronchiectasis caused by human immunodeficiency virus infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;\n5. Combined with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n6. Patients with previous or current smoking history;\n7. Pregnant or lactating women;\n8. Currently participating in other interventional clinical research;\n9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":77,"type":21},44,"To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis",[27,25,56,80,81,82,83],"Airway Clearance","Mucus Plug","Amphotericin B","Bronchoscope",[25,27,82,85,80,86],"bronchoscope","mucus plug","2026-01-15",{"date":89,"type":34},"2026-01-23",{"date":91,"type":34},"2026-01-10",{"date":66,"type":21},{"name":40,"class":41},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":68},"100617075","effects-of-environmental-fungal-exposure-on-bronchial-asthma-abpa-and-bronchiectasis-100617075","NCT07313904","Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis","Effects of Environmental Fungal Exposure on Bronchial Asthma, Allergic Bronchopulmonary Aspergillosis (ABPA), and Bronchiectasis","Inclusion Criteria:\n\n1. Age range of 18-80 years old (including 18 and 80 years old), gender and race are not limited;\n2. No history of asthma, ABPA, or other chronic respiratory diseases.\n3. No history of allergic diseases, such as allergic rhinitis, eczema, or food allergies.\n4. Pulmonary function is normal or close to the normal range.\n5. Laboratory testing:\n\n1\\. Blood routine: High sensitivity C-reactive protein, white blood cells, neutrophils, lymphocytes, and monocytes are all within the normal range.\n\nAllergen testing: IgE levels for common allergens such as dust mites, cat hair, dog hair, cockroaches, mold, and pollen are normal or close to the normal range.\n\nExclusion Criteria:\n\n1. Suffering from bronchial asthma ABPA、 Bronchiectasis or other respiratory diseases: chronic obstructive pulmonary disease, active pulmonary tuberculosis, pulmonary embolism, lung cancer, pneumothorax, hemoptysis, pulmonary arterial hypertension, interstitial lung disease, etc;\n2. Cancer patients who suffer from serious other systemic diseases, such as myocardial infarction, stroke, hypertensive crisis or refractory hypertension, severe arrhythmia, heart failure, aortic aneurysm, liver failure, renal failure, hematological disorders, etc., and have recently been discovered or are currently receiving treatment;\n3. Four weeks prior to enrollment, systemic use of antibiotics, antifungal drugs, immunosuppressants, cytotoxic agents, hormones, etc;\n4. Other individuals with contraindications for induced sputum testing:",true,"80 Years",{"count":104,"type":21},125,"This study is a prospective, observational study of patients aged 18-80 years with clinical diagnosis of bronchial asthma, allergic bronchopulmonary aspergillosis (ABPA), bronchiectasis and healthy subjects. Among them, the bronchial asthma group will be divided into asthma control group, asthma partial control group and asthma uncontrolled group according to the GINA asthma control classification. Record the baseline information of the subjects in detail, including basic information, disease course, smoking, previous acute attacks and hospitalizations, long-term medication, etc. (including the frequency, dose and duration of ICS use, antifungal drug type, dose, duration of use, and course of treatment), and evaluate and record environmental factors (such as indoor).Humidity, temperature, ventilation, pet keeping, plant planting, etc.) and other lifestyle factors that may affect disease control and fungal exposure. The patient's disease status was assessed using questionnaire scores.\n\nSputum samples were taken at the time of enrollment.Set (asthma ABPA group uses sputum induction), pulmonary function test and bronchodilator test, FeNO measurement (asthma ABPA group only), blood routine test, Aspergillus-specific IgE and IgG detection, total immunoglobulin IgE, allergen detection, etc. Dust was collected indoors (bedrooms), outdoor (balconies) and on the surface of air conditioners or fans (if applicable) in the subject's living environment, and environmental data such as ambient temperature, humidity, and particulate matter concentration were recorded. 18S rRNA technology was used for sputum and dust fungus detection, and ELISA was used for asthmatitis symptomatic markers, which assess the impact of fungal infections on the disease. Follow-up for each subject 6 months, 6 months after enrollment, the patient's symptom changes, acute exacerbations\u002Fexacerbations, and prognosis were recorded, and relevant questionnaire scores were completed.",[107,108,109,27],"Environmental Exposure","Asthma","Bronchiectasis","2025-12-17",{"date":112,"type":34},"2026-01-02",{"date":114,"type":34},"2025-07-23",{"date":116,"type":21},"2026-06-30",{"name":118,"class":119},"First Affiliated Hospital of Ningbo University","NETWORK"]